Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: Results of the helping evaluate exenatide in patients with diabetes compared with long-acting insulin (HEELA) study

Diabetes, Obesity and Metabolism

Volumn 11, Issue 12, 2009, Pages 1153-1162

  Davies, M J ^a   Donnelly, R ^b   Barnett, A H ^c   Jones, S ^d   Nicolay, C ^e   Kilcoyne, A ^f  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d JAMES COOK UNIVERSITY HOSPITAL   (United Kingdom)

^e LILLY DEUTSCHLAND GMBH   (Germany)

^f ELI LILLY AND COMPANY   (United States)

Author keywords

Exenatide; Glucagon like peptide 1 (GLP 1) agonist; Glycaemic control; Insulin glargine; Randomized controlled trial; Type 2 diabetes; Weight gain

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; EXENDIN 4; HEMOGLOBIN A1C; INSULIN GLARGINE; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA;

ACUTE KIDNEY FAILURE; ADD ON THERAPY; ADULT; ARTICLE; ASTHMA; BEDTIME DOSAGE; BODY MASS; BODY WEIGHT; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DIARRHEA; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPNEA; FEMALE; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUROLOGIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; VOMITING; WEIGHT GAIN;

DIABETES MELLITUS, TYPE 2; FEMALE; GREAT BRITAIN; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN, LONG-ACTING; MALE; MIDDLE AGED; PEPTIDES; TREATMENT OUTCOME; VENOMS; WEIGHT GAIN;

EID: 70450199755     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2009.01154.x     Document Type: Article

References (25)

1. Mokdad AH, Ford ES, Bowman BA. Prevalence of obesity, diabetes, and obesity related health risk factors, 2001. JAMA 2003, 289:76-79.
2. Gæde P, Lund-Andersen H, Parving H-H, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008, 358:580-589.
3. Position statement: standards of medical care in diabetes. Diabetes Care 2009, 32:S13-S61. American Diabetes Association, (Suppl 1):
4. Kahn SE, Haffner SM, Heise MA. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006, 355:2427-2443.
5. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853. UK Prospective Diabetes Study (UKPDS) Group
6. Nathan DM, Buse JB, Davidson MB. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006, 29:1963-1972.
7. Raskin PR, Hollander PA, Lewin A. Basal insulin or premix analogue therapy in type 2 diabetes patients. Eur J Intern Med 2007, 18:56-62.
8. Holman RR, Thorne KI, Farmer AJ. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007, 357:1716-1730.
9. Riddle MC. Timely initiation of basal insulin. Am J Med 2004, 116:3S-9S. (Suppl. 3A):
10. Cvetković RS, Plosker GL. Exenatide: a review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and/or a sulfonylurea). Drugs 2007, 67:935-954.
11. Barnett A. Exenatide. Expert Opin Pharmacother 2007, 8:2593-2608.
12. Barnett AH, Burger J, Johns D. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther 2007, 29:2333-2348.
13. Heine RJ, Van Gaal LF, Johns D. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005, 143:559-569.
14. Glass LC, Qu Y, Lenox S. Effects of exenatide versus insulin analogues on weight change in subjects with type 2 diabetes: a pooled post-hoc analysis. Curr Med Res Opin 2008, 24:639-644.
15. Riddle MC, Rosenstock J, Gerich J. The Treat-to-Target Trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetes patients. Diabetes Care 2003, 26:3080-3086.
16. www.dh.gov.uk/en/Policyandguidance/organisationpolicy/primarycare/primarycarecontracting/QOF/DH_4125653, UK Department of Health, Quality and Outcomes Framework (updated 2004). Available from URL:, Accessed 5 January 2009.
17. Goldberg RB, Holman R, Drucker DJ. Clinical decisions: management of type 2 diabetes. N Engl J Med 2008, 358:293-297.
18. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457-2471.
19. Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as 'add-on' therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006, 29:1269-1274.
20. Wilson PW, D'Agostino RB, Sullivan L, Parise H, Kannel WB. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med 2002, 162:1867-1872.
21. Nauck MA, Duran S, Kim D. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 2007, 50:259-267.
22. Massi Benedetti M, Humburg E, Dressler A, Ziemen M. A one-year, randomized, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Horm Metab Res 2003, 35:189-196.
23. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2672.. The ADVANCE Collaborative Group
24. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545-2559. The Action to Control Cardiovascular Risk in Diabetes Study Group
25. Dluhy RG, McMahon GT. Editorial: Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med 2008, 358:2630-2633.